AcuityMD Closes $80M Series C Led by StepStone Group

Why It Matters

The capital infusion accelerates AI‑driven commercialization in a $1 trillion‑plus MedTech market, giving sales teams actionable intelligence that can cut cycle times and boost revenue. It also signals strong investor confidence in vertical AI solutions that address fragmented healthcare data.

Key Takeaways

• AcuityMD raised $80 M Series C, valuation $955 M
• Funding led by StepStone; Benchmark, Redpoint, ICONIQ, Atreides participated
• Capital will build agentic AI, expand data model, support product lifecycle
• AcuityAI beta offers real‑time, context‑rich recommendations to sales reps
• Platform serves 400+ MedTech firms, identified $34 B pipeline opportunities

Pulse Analysis

The medical‑device sector is on a trajectory toward a $1 trillion market by 2035, driven by an expanding portfolio of AI‑enabled products and ongoing hospital consolidation. While clinicians benefit from smarter diagnostics, commercial teams still wrestle with siloed data sources—claims databases, FDA filings, and internal CRM systems—that impede precise targeting. AcuityMD’s platform tackles this fragmentation by constructing a continuously updated MedTech ontology, a knowledge graph that maps physicians, procedures, reimbursement rules, and product relationships. By layering a client’s proprietary data onto this graph, the solution creates a unified market view that far exceeds traditional CRM capabilities.

The recent $80 million Series C, led by StepStone Group, underscores the growing appetite for vertical AI tools that go beyond clinical use cases. Investors such as Benchmark and ICONIQ see the commercial side of healthcare as a high‑margin frontier where AI can generate immediate ROI. AcuityMD plans to allocate the capital toward "agentic AI"—software that autonomously generates actionable recommendations for reps, managers, and marketers—while also expanding its data model to cover the entire product lifecycle, from pre‑market planning to post‑launch adoption. This strategic focus positions the company to capture a larger share of the $34 billion pipeline it has already identified for its customers.

For MedTech firms, the practical impact is clear: faster insight delivery, more accurate account prioritization, and the ability to react in real time to events such as surgery cancellations or new contract announcements. Early adopters like Kuros Biosciences report that AcuityAI reduces research time from hours to minutes, enabling reps to engage physicians with tailored, data‑backed conversations. As the industry continues to adopt AI at scale, platforms that embed contextual intelligence directly into sales workflows—like AcuityMD—will become indispensable, reshaping how medical technologies reach the market and ultimately accelerating patient access to innovative treatments.